Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Rollover Study of Doravirine/Islatravir in HIV-1 Infection
jRCT2031210528Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of doravirine and islatravir in Human immunodeficiency virus infection type 1, sponsored by Merck & Co. Primary endpoint: Percentage of participants experiencing serious adverse events or discontinuing study intervention due to an adverse event. Started Jan 2022; status: active, not recruiting.
02
Drugs
doravirineislatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2031210528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210528.